PTC Therapeutics, Inc. (PTCT) SEC Filings & Earnings Calls

Regulatory approval risk; BLA submission not yet complete; post-approval study requirements.

“BLA submission expected Q4 2026; accelerated approval pathway with post-marketing commitments.”

Acquisition subject to bankruptcy court approval and HSR; milestone payments contingent on FDA approval

“Conditions include Bankruptcy Court order and HSR waiting period; milestones tied to accelerated and full FDA approval”

Acquisition subject to bankruptcy court approval, antitrust review, and other closing conditions.

“The Acquisition remains subject to finalization of definitive documentation, bankruptcy court approval, antitrust review, and the satisfaction of other customary closing conditions.” · word for word

Translarna revenue decline due to regulatory setbacks

“The decrease in Translarna sales is primarily due to the EC's adoption of the CHMP's negative opinion.” · word for word

Emflaza generic competition

“With the expiration of this orphan drug exclusivity, we have seen an increase in competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue.” · word for word

Vatiquinone FDA CRL

“In August 2025, the FDA issued a complete response letter related to the NDA stating that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional adequate and well-controlled study would be needed to support NDA resubmission.” · word for word

Accumulated deficit

“As of June 30, 2026, we had an accumulated deficit of $2,883.5 million.” · word for word

Pipeline dependency: clinical trial risks for votoplam and vatiquinone.

“PIVOT-HD 24-month results; PROVE-FA study to support NDA resubmission.”

Regulatory risk: FDA engagement for votoplam and vatiquinone NDA.

“Plan to engage with FDA in 2H 2026 to discuss PIVOT-HD 24-month results.” · word for word

Convertible notes increase potential dilution and add debt, though coupon is 0%.

“$550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031.”

Potential dilution from convertible notes if converted.

“0.00% Convertible Senior Notes due 2031”

Translarna revenue concentration and regulatory risk

“There is a substantial risk that as a result of the EC’s adoption of the CHMP’s negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.” · word for word

Emflaza generic competition

“With the expiration of this orphan drug exclusivity, we have seen an increase in competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue.” · word for word

Accumulated deficit and need for additional funding

“As of March 31, 2026, we had an accumulated deficit of $2,967.0 million.” · word for word

Generic erosion of Emflaza and Translarna revenue decline.

“Emflaza revenue down to $21.5M from $47.8M due to generic erosion; Translarna down to $59.0M from $86.2M.”

Translarna conditional marketing authorization not renewed in EU

“where Translarna’s conditional marketing authorization was not renewed but business was maintained in over 50% of countries” · word for word

Emflaza faces increased generic competition in U.S.

“against challenges in the U.S. to Emflaza due to an increase of competition from generics” · word for word

Vatiquinone received complete response letter from FDA

“although eventually we received a complete response letter from the FDA, we continue to work with FDA on next steps for the vatiquinone program” · word for word

Declining legacy product revenues (Translarna, Emflaza) may pressure future top-line growth.

“Translarna net product revenues $235.3M FY2025 vs $321.1M FY2024; Emflaza $146.4M vs $207.2M.”

Dependence on Sephience launch success for future growth; competitive and regulatory risks.

“Sephience is a new product; global expansion to 20-30 countries by end of 2026; FDA interactions for other pipeline programs.”

Translarna authorization loss in EEA

“There is a substantial risk that as a result of the EC’s adoption of the CHMP’s negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.” · word for word

Emflaza generic competition

“The decrease in Emflaza sales is primarily driven by additional generic competition.” · word for word

Drug pricing regulation (IRA)

“the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (negotiated prices for the first 10 selected drugs effective beginning in 2026), with prices that can be negotiated subject to a cap” · word for word

Supply chain dependency on third-party manufacturers

“We contract with third parties for the manufacture and distribution of our products and certain of our product candidates, which may increase the risk that we will not have sufficient quantities of our products or product candidates.” · word for word

Historical operating losses

“While we have generated net income in the year ended December 31, 2025, we have historically incurred significant operating losses.” · word for word

Regulatory failure eliminates US market opportunity for Translarna, a key pipeline asset.

“Withdrawal of Translarna NDA resubmission after FDA feedback indicates data insufficient for approval.”

Preliminary results subject to audit

“Preliminary unaudited financial information for FY2025.”

Loss of future royalty income from Evrysdi; now owns 0% of royalty.

“As a result of the sale, RPI owns 100% of the Royalty and the Company owns 0% of the Royalty.” · word for word

DMD franchise revenue decline

“Translarna revenue -30% YoY; Emflaza -32% YoY.”

Sephience launch execution risk

“Early launch stage; 341 patients on commercial therapy worldwide.”

Generic competition for Emflaza

“The decrease in Emflaza sales is primarily driven by additional generic competition.” · word for word

Translarna EU authorization not renewed

“The decrease in Translarna sales is primarily due to the EC’s adoption of the CHMP’s negative opinion.” · word for word

FDA CRL for vatiquinone

“In August 2025, the FDA issued a complete response letter related to the NDA stating that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional adequate and well-controlled study would be needed to support NDA resubmission.” · word for word

Dependence on Novartis collaboration for profitability

“Collaboration and license revenue was $998.4 million for the nine months ended September 30, 2025, an increase of $998.4 million, or 100%, from $0.0 million for the nine months ended September 30, 2024.” · word for word